在复杂的尿路感染中,cefepime-taniborbactam增加了治疗成功率,而meropenem则在19至23天内增加了治疗成功率
1University of Texas MD Anderson Cancer Center, Houston, Texas, USA (B.G.).
Annals of internal medicine
|June 3, 2024
概括
塞费皮姆-坦尼博巴克坦在治疗复杂的尿路感染 (cUTI) 中表现出高疗效. 这种新型抗生素组合为耐药细菌感染的患者提供了一个有前途的选择.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 复杂的尿路感染 (cUTI) 由于抗菌素耐药性增加而构成重大挑战.
- 在cUTI中,对多抗药性格拉姆阴性感染的有效治疗选择有限.
- 新型抗菌剂对于对抗具有挑战性的尿病原体至关重要.
研究的目的:
- 评估Cefepime-taniborbactam与成人复杂尿路感染 (cUTI) 的美洛相比的疗效和安全性.
- 评估患有由特定的格拉姆阴性病原体引起的感染的患者的治疗结果,包括具有抗卡巴胺耐药性的患者.
主要方法:
- 进行了一项3期,随机,双盲,非劣势性试验 (CERTAIN-1).
- 成年患有cUTI的患者被随机分配给静脉注射塞费皮姆-塔尼博巴克坦或梅罗.
- 关键的终点包括治疗试验访问时的临床治愈率和微生物根除率.
主要成果:
- 塞费皮姆-坦尼博巴克坦在治疗皮肤炎的临床治愈率方面实现了与美洛姆的非劣势.
- 在cefepime-taniborbactam手臂中观察到高微生物根除率,包括由耐药生物体引起的感染.
- 塞费皮姆-坦尼博巴克坦的安全性概况与梅洛相似.
结论:
- 塞菲皮姆-塔尼博巴克坦是复杂的尿路感染 (cUTI) 的有效和安全的治疗选择.
- 这种组合疗法为患有易受阴性病原体引起的感染的患者提供了有价值的替代方案,包括对其他药物耐药的病原体.
- 这些发现支持cefepime-taniborbactam在解决对抗耐药性尿病原体的新抗生素未满足需求方面的作用.
更多相关视频
08:30One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures
Published on: July 9, 2012
25.5K
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
7.0K
相关概念视频
01:27Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
01:28Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
01:28Pneumonia IV: Management
322
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
322
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
363
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
363